Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014


#224635

90pages

Global Markets Direct

$ 2000

In Stock

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

Summary

Global Markets Directs, Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview 7
Therapeutics Development 8
Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Overview 8
Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 9
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 10
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 15
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Genentech, Inc. 17
MedImmune, LLC 18
Novartis AG 19
Ono Pharmaceutical Co., Ltd. 20
Pfizer Inc. 21
Merck KGaA 22
Oncolytics Biotech Inc. 23
Panacea Biotec Limited 24
PCI Biotech AS 25
Glycotope GmbH 26
VentiRx Pharmaceuticals, Inc. 27
Immunovative Therapies, Ltd. 28
AlphaMab Co., Ltd 29
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
pelareorep - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
nivolumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
dacomitinib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
bleomycin sulfate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
cetuximab biobetter - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
futuximab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
motolimod - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
duligotuzumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
durvalumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AlloVax - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BYL-719 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cetuximab biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cetuximab biosimilar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
cetuximab biosimilar - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 67
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 86
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 87
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 88
Featured News & Press Releases 88
May 15, 2013: Boehringer Ingelheim To Present Five Abstracts For Afatinib At ASCO 2013 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90

List of Tables
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2014 8
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2014 16
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H2 2014 17
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2014 18
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2014 19
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 20
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2014 21
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H2 2014 22
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2014 23
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2014 24
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2014 25
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2014 26
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 27
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2014 28
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 67
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2014 86
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2014 87

List of Figures
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2014 8
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 13
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Top 10 Target, H2 2014 31
Number of Products by Stage and Top 10 Target, H2 2014 32
Number of Products by Top 10 Mechanism of Action, H2 2014 33
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 34
Number of Products by Top 10 Route of Administration, H2 2014 35
Number of Products by Stage and Top 10 Route of Administration, H2 2014 36
Number of Products by Top 10 Molecule Type, H2 2014 37
Number of Products by Stage and Top 10 Molecule Type, H2 2014 38

NA

NA